Lisata Therapeutics Inc. (8NE)
XDUS 
Summary
8NE Chart
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value right worth up to an additional $3.00 per share tied to drug development milestones.
Lisata Therapeutics to be acquired by Kuva Labs
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing therapies to treat advanced solid tumors and other serious diseases, announced that it has agreed to be acquired by privately held Kuva Labs. Under the terms of a definitive agreement, Kuva will launch a tender offer to purchase all outstanding Lisata shares for $5 per share in cash at closing, plus one contingent value right (CVR) per share.
Lisata regains China rights to pancreatic cancer drug
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has mutually terminated a licensing and collaboration agreement with China's Qilu Pharmaceutical, regaining full rights to its cancer drug candidate certepetide in the Greater China region. The February 2021 agreement granted Qilu exclusive rights to develop and commercialize certepetide in Mainland China, Hong Kong, Macau and Taiwan.
Lisata Therapeutics Inc. (8NE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lisata Therapeutics Inc. ever had a stock split?
Lisata Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | David J. Mazzo CEO | XDUS Exchange | US1280583022 ISIN |
| US Country | 26 Employees | - Last Dividend | 15 Sep 2022 Last Split | 1 Mar 1999 IPO Date |
Overview
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing innovative therapies for the treatment of solid tumors and various diseases. Founded in 1980, the company has been at the forefront of research and development in oncology and other critical areas of medicine. Headquartered in Basking Ridge, New Jersey, Lisata Therapeutics aims to deliver breakthrough treatments that can significantly improve patient outcomes. With a focus on identifying and advancing promising drug candidates, the company is committed to addressing some of the most challenging medical conditions faced today.
Products and Services
- LSTA1
This product candidate is currently in Phase 2a and 2b clinical studies for the treatment of solid tumors. It shows particular promise in the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) when used in combination with various anti-cancer regimens. LSTA1 represents Lisata Therapeutics' dedication to combating one of the most aggressive and hard-to-treat cancers.
- XOWNA
XOWNA is another innovative treatment under development, currently undergoing a Phase IIa clinical trial. It is designed for the treatment of coronary microvascular dysfunction, a condition that affects the small vessels supplying blood to the heart muscle. This represents a significant advancement in addressing a key area of unmet medical need in cardiovascular disease.
- CD34+ Cell Therapy
Targeting chronic kidney disease, this CD34+ cell therapy is among Lisata Therapeutics' novel approaches to treating chronic conditions with high unmet clinical needs. By leveraging the potential of CD34+ cells, this therapy aims to offer new hope to patients suffering from chronic kidney disease, showcasing the company's commitment to innovating in areas where traditional treatments have fallen short.
